Neuromodulation for treatment-refractory major depressive disorder
Open accessThe DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Abstract
Major depressive disorder is among the most prevalent psychiatric disorders and is a leading cause of morbidity and lost productivity.[1][1] The 1-year prevalence of major depressive disorder in the Canadian population is 3.2%–4.6%.[2][2] A large, multisite prospective trial showed that only 28%
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Rossi, S., Hallett, M., Rossini, P. M., & Pascual-Leone, A. (2009) · Clinical Neurophysiology · doi:10.1016/j.clinph.2009.08.016 · Cited by 5,367 · cited 1×
“More serious adverse effects include the emergence of hypomania or suicidal behaviour in less than 1% of patients.(41) Very rarely (< 0.”
BackgroundTrivedi, M. H., Rush, A. J., Wisniewski, S. R., Nierenberg, A. A., Warden, D., Ritz, L., Norquist, G., Howland, R. H., Lebowitz, B., McGrath, P. J., et al. (2006) · American Journal of Psychiatry · doi:10.1176/appi.ajp.163.1.28 · Cited by 3,879 · cited 1×
“A large, multisite prospective trial showed that only 28% of patients ex peri ence remission following monotherapy with a serotonin reuptake inhibitor.(3) Further, remission rates following antidepressant use decrease with each successive treatment failure, such that after 12 months of follow-up and up to 4 attempts a…”
Background(2003) · The Lancet · doi:10.1016/s0140-6736(03)12705-5 · Cited by 1,706
George, M. S., Lisanby, S. H., Avery, D., McDonald, W. M., Durkalski, V., Pavlicova, M., Anderson, B., Nahas, Z., Bulow, P., Zarkowski, P., et al. (2010) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2010.46 · Cited by 1,092 · cited 1×
“George et al.(30) Multicentre RCT, sham control 190 patients; MDD • 15% response (v.”
BackgroundDeep Brain Stimulation to Reward Circuitry Alleviates Anhedonia in Refractory Major Depression
Schlaepfer, T. E., Cohen, M. X., Frick, C., Kosel, M., Brodesser, D., Axmacher, N., Joe, A. Y., Kreft, M., Lenartz, D., & Sturm, V. (2008) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301408 · Cited by 1,027
Deep Brain Stimulation of the Ventral Capsule/Ventral Striatum for Treatment-Resistant Depression
Malone, D. A., Dougherty, D. D., Rezai, A. R., Carpenter, L. L., Friehs, G. M., Eskandar, E. N., Rauch, S. L., Rasmussen, S. A., Machado, A. G., Kubu, C. S., et al. (2009) · Biological Psychiatry · doi:10.1016/j.biopsych.2008.08.029 · Cited by 897
Hamilton, J. P., Etkin, A., Furman, D. J., Lemus, M. G., Johnson, R. F., & Gotlib, I. H. (2012) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2012.11071105 · Cited by 866
Bewernick, B. H., Hurlemann, R., Matusch, A., Kayser, S., Grubert, C., Hadrysiewicz, B., Axmacher, N., Lemke, M., Cooper-Mahkorn, D., Cohen, M. X., et al. (2010) · Biological Psychiatry · doi:10.1016/j.biopsych.2009.09.013 · Cited by 865
Translational principles of deep brain stimulation
Kringelbach, M. L., Jenkinson, N., Owen, S. L. F., & Aziz, T. Z. (2007) · Nature Reviews Neuroscience · doi:10.1038/nrn2196 · Cited by 853
Sackeim, H. A., Haskett, R. F., Mulsant, B. H., Thase, M. E., Mann, J. J., Pettinati, H. M., Greenberg, R. M., Crowe, R. R., Cooper, T. B., & Prudic, J. (2001) · JAMA · doi:10.1001/jama.285.10.1299 · Cited by 686 · cited 1×
“Sackeim et al.(12) Multicentre RCT, sham control 290 patients; MDD • Decreased 6-mo relapse rates following ECT with combination of nortriptyline and lithium (39%) v.”
Background
Cited by
Mir-Moghtadaei, A., Caballero, R., Fried, P., Fox, M. D., Lee, K., Giacobbe, P., Daskalakis, Z. J., Blumberger, D. M., & Downar, J. (2015) · Brain Stimulation · doi:10.1016/j.brs.2015.05.008 · Cited by 269
Self-citationBlumberger, D. M., Vila-Rodriguez, F., Wang, W., Knyahnytska, Y., Butterfield, M., Noda, Y., Yariv, S., Isserles, M., Voineskos, D., Ainsworth, N. J., et al. (2021) · Brain Stimulation · doi:10.1016/j.brs.2021.09.003 · Cited by 81
Self-citationAbdelnaim, M. A., Langguth, B., Deppe, M., Mohonko, A., Kreuzer, P. M., Poeppl, T. B., Hebel, T., & Schecklmann, M. (2020) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2019.00929 · Cited by 50
Update on neuromodulation for treatment-resistant depression
Bewernick, B., & Schlaepfer, T. E. (2015) · F1000Research · doi:10.12688/f1000research.6633.1 · Cited by 47
Challenging Treatment-Resistant Major Depressive Disorder: A Roadmap for Improved Therapeutics
de Sousa, R. T., V. Zanetti, M., R. Brunoni, A., & Machado-Vieira, R. (2015) · Current Neuropharmacology · doi:10.2174/1570159x13666150630173522 · Cited by 43
“Nevertheless, some studies have shown good response rates in highly refractory samples [151] and a recent meta-analysis found an effect size of 1.”
Metadata
- Authors
- Lipsman, N., Sankar, T., Downar, J., Kennedy, S. H., Lozano, A. M., & Giacobbe, P.
- Venue
- Canadian Medical Association Journal
- Publisher
- CMA Impact Inc.
- Published
- 2013-07-29
- Volume
- 186
- Issue
- 1
- Pages
- 33-39
- ISSN
- 0820-3946 (ISSN-L)
- 1488-2329
- OpenAlex
- W2129573214
- Cited by
- 59
- References
- 23
- FWCI
- 2.61
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Neuromodulation for treatment-refractory major depressive disorder. https://app.cochat.ai/papers/10.1503/cmaj.121317
- The paper
- Lipsman, N., Sankar, T., Downar, J., Kennedy, S. H., Lozano, A. M., & Giacobbe, P. (2014). Neuromodulation for treatment-refractory major depressive disorder. Canadian Medical Association Journal. https://doi.org/10.1503/cmaj.121317
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.